Thrombotic thrombocytopenic purpura temporally associated with BNT162b2 vaccination in an adolescent successfully treated with caplacizumab

Br J Haematol. 2022 Jan;196(1):e11-e14. doi: 10.1111/bjh.17782. Epub 2021 Aug 17.

Amrit Kirpalani^{1

2}, Justin Garabon¹, Kiersten Amos¹, Serina Patel^{1

2}, Ajay P Sharma^{1

2}, Saptharishi Lalgudi Ganesan^{1

2}, Michelle Barton^{1

2}, Chantel Cacciotti^{1

2}, Sarah Leppington³, Linda Bakovic^{4

5}, Shih-Han Susan Huang^{2

6}, Michael J Knauer⁷, Soumitra Tole^{1

2}

¹ Department of Pediatrics, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
² Department of Pediatrics, London Health Sciences Centre, London, ON, Canada.
³ Children's Hospital, London Health Sciences Centre, London, ON, Canada.
⁴ Department of Pediatrics, Northern Ontario School of Medicine, Thunder Bay, ON, Canada.
⁵ Department of Pediatrics, Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada.
⁶ Department of Medicine, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
⁷ Department of Pathology and Laboratory Medicine, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada.

No abstract available

Keywords: COVID-19; TTP; adolescent; caplacizumab; vaccine.

Publication types